BioDuro & Silexon Form Strategic Collaboration to Develop New Anti-Cancer Drugs

SAN DIEGO and SHANGHAI, December 03, 2020 – BioDuro LLC, a leading global life sciences contract research, development and manufacturing organization (CRDMO), and Silexon, a cutting-edge AI-empower
December 03, 2020

Congratulations! Innocare‘s Orelabrutinib has been approved by NMPA for Commercial in China!

InnoCare Pharma's Orelabrutinib approved by NMPA for treating mantle cell lymphoma and chronic lymphocytic leukemia patients who've had prior treatment.
November 22, 2020

Congratulations to TaiGen’s Flu Antiviral Drug TG-1000 for Receiving FDA approval of IND

TaiGen Biotechnology celebrates FDA approval for clinical trials of TG-1000, a novel cap-dependent endonuclease inhibitor for influenza A and B treatment.
November 02, 2020

Congratulations to Longwood Biopharmaceuticals for LW402 Accepted for Clinical Trial

Longwood Biopharmaceuticals' LW402 and tablet (CXHL2000303-305) approved by CDE, NMPA for clinical trials, targeting Rheumatoid Arthritis treatment.
September 26, 2020

BioDuro and Sundia Partner as an Industry Leading Contract Research, Development and Manufacturing Organization

San Diego and Shanghai, September 25, 2020 – BioDuroBioDuro, a global life science research and development organization backed by Advent International (“Advent”), and Sundia, a leading contract res
September 25, 2020
Total 84 12...567891011...1617
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all